Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Add-on immunotherapy prolongs survival in advanced endometrial cancer
03 Nov 2023
bởiJairia Dela Cruz
In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.
03 Nov 2023

Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
bởiAudrey Abella
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
03 Nov 2023

Esketamine outperforms quetiapine in head-to-head depression trial
30 Oct 2023
bởiJairia Dela Cruz
In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.
30 Oct 2023






